Carisma Therapeutics Announces Changes to its Board of Directors
Carisma Therapeutics (Nasdaq: CARM) has announced changes to its Board of Directors.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Carisma Therapeutics (Nasdaq: CARM) has announced changes to its Board of Directors. Sohanya Cheng, MBA will join the board effective October 31, 2024, while Michael Torok will step down on the same date due to other professional commitments. Board Chair Sanford Zweifach highlighted Cheng's experience in oncology, leadership, strategic planning, and commercialization as valuable assets for advancing the company's portfolio. Cheng expressed enthusiasm about supporting Carisma's mission in developing innovative immunotherapies and strengthening its position in engineered macrophages.
Positive
- Addition of board member with expertise in oncology and commercialization
- Strategic strengthening of leadership team with commercial experience
Negative
- Loss of board member Michael Torok
Details
News Market Reaction – CARM
The recorded move for CARM in the trading session of this news was -2.65%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Appointment of Sohanya Cheng
Resignation of Michael Torok
"It's a pleasure to welcome Sohanya to our Board," said Sanford Zweifach, Chair of the Carisma Board. "Her broad experience in oncology, alongside her skills in leadership, strategic planning, and commercialization, will be instrumental as we continue to advance our portfolio and strengthen our foundation. We are also thankful to Michael for his valuable service and wish him all the best in his next chapter."
"I am excited to join Carisma's Board and collaborate with the management team as the Company advances its mission to deliver innovative immunotherapies to patients facing serious diseases," said Ms. Cheng. "I look forward to sharing my insights and supporting the Company's strategic goals as it solidifies its position as a leader in engineered macrophages within oncology and beyond."
About Sohanya Cheng, MBA
Ms. Cheng brings over 20 years of experience in biopharmaceutical commercialization and research, with a strong focus on oncology. She currently serves as the EVP, Chief Commercial Officer, and Head of Business Development at Karyopharm Therapeutics. Prior to this, she was Vice President, Head of Marketing and Corporate Affairs at Arrowhead Pharmaceuticals. Ms. Cheng also spent over a decade at Amgen in various leadership roles, including Executive Director, Head of Marketing & Sales for multiple myeloma and Head of Oncology National Sales, contributing to the commercialization of key oncology brands. She holds an MBA from the MIT Sloan School of Management and both a BSc and MA from the University of
About Carisma
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. We have created a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes, cells that play a crucial role in both the innate and adaptive immune response. Carisma is headquartered in
Investors:
Shveta Dighe
Head of Investor Relations
investors@carismatx.com
Media Contact:
Julia Stern
(763) 350-5223
jstern@realchemistry.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/carisma-therapeutics-announces-changes-to-its-board-of-directors-302292071.html
SOURCE Carisma Therapeutics Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.